Clinical Trials Browser

Phase 3 × Carcinoma, Medullary × cabozantinib × Clear all

NCT04211337 2025-04-20

LIBRETTO-531

Phase 3 Active not recruiting

291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

NCT04760288 2024-01-05

AcceleRET-MTC

Phase 3 Withdrawn

Carcinoma, Medullary